Surgery Still Beats Ozempic and Other GLP-1 Drugs in Real-World Weight Loss Study

As for weight loss, the operation still prefers. Today, the study today tends to lose more weight than people who have the most popular, most effective GLP-1 medication today.

Scientists from the University of New York, analyzing real world information from obesity patients. People who received the operation lost their five times more weight in two years, and one GLP-1 medication was more average than those determined. The findings also say that the GLP-1 medicines are not effective as in clinical trials in the real world.

“I think if a new popular drug is going out, you take it with a grain of grain. I think that the real researcher Karan Chabra, Bariatric surgeon and operation for several years to exit the real world information.

Bariatric surgery – especially goal gastrectomy and stomach Bypass – long ago considered the most effective treatment for obesity. People usually lose between 20% and 30% of their initial weights after surgery and often practice Long-term improvements in general health.

However, in recent years, the emergence of new GLP-1 medications as semaglutide (active ingredients in Ozemptic and Wegovy) dramatically changed the area of ​​obesity. These drugs are usually more effective (and safer) More than 10% and 20% of people between 10% and 20% in clinical trials. And they also linked Health benefits that goes beyond losing weight.

At first glance, the data can approach GLP-1 medications or Even overlapping– Efficiency of bariatric transaction. However, according to CHHABRA, among these two different obesity treatment between real world patients have not had a serious occurrence comparison with these two different types of obesity.

Chhabra and colleagues, colleagues, 2018 and 2024 can be compared to other health status and other health conditions and other health conditions (either in GLP-1 therapy) or GLP-1 therapy (either SemOllutide or Tirzepatide). Patients and their weight loss results were watched for two years.

On average, surgical patients have 58 pounds (about 24% of total weight, about 24%), 12 kilos of 12 kilos (4.7% of total weight 4.7%). The results are a year better for people who are on medication for a year (7% weight loss loss) and pirzepatide, which are the newest and most effective GLP-1 medication. However, the results were still short of the successes taken by the operation – not to mention the results of previous clinical trials.

The team’s consequences were Submitted This week, the annual meeting of the American and Bariatric Surgery (ASMBs).

According to Çhabra, there are several reasons why these drugs are not successful as it seems to be tested. 70% of the GLP-1 patients, for example, stop using the use of the first year. Some, side effects usually have more than a heartbreaking symptoms like nausea and diarrhea; Others may not only stop because they could not pay the drugs (GLP-1 medications are often covered with insurance and can be patronized for $ 1,000 per month). Many of the GLP-1 patients in the study will not reach the maximum dose.

Chhabra doubts that many people in the true world will be in clinical judgment of supportive care and persecutors. GLP-1 medicines burned the industry, for example, for example, people are often identified by drugs remotely, they will never interact in person. (Until recently, people can easily access the ink version of semaglutiside and inserts with less security or efficiency.)

Researchers do not receive the GLP-1 medicine for obesity and not say that the Bariatric transaction should be an ideal choice for everyone. Some people can prefer a disposable treatment, for example, there may be insurance or sources to cover long-term GLP-1 therapy. Others are not GLP-1 therapy, but with other pre-existing conditions that can switch to any invasive procedure or complicate the surgery.

At the end of the day, people should be aware of the relevant positive and disadvantages of these treatments, and according to ChaBra, they must manage those who choose to go with GLP-1S.

“They need to know that at least this in the true world will not have anything to lose weight, and they should also know that they have a life treatment.” “There is no protocol for people to lose weight after people stop the drugs, so people are important to promote these truths. And I am concerned about the fact that many people start with them.”

The team’s next, GLP-1 plans to transmit more information to clarify that the real life patients in the therapy are expected as expected.